Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Renal and urinary disorders – page 26

  • 580 clinical trials
  • 226 recruiting
  • 296 conditions
  • 27 countries

Conditions in this area

296 conditions with trials, the busiest first

Chronic kidney disease61Bladder cancer54Transitional cell carcinoma46Renal cell carcinoma42Bladder transitional cell carcinoma33IgA nephropathy23Acute kidney injury21Non-small cell lung cancer19Lupus nephritis18Clear cell renal cell carcinoma17Urinary tract infection17Paroxysmal nocturnal haemoglobinuria16Breast cancer14Metastatic renal cell carcinoma14End stage renal disease13Congenital cystic kidney disease12Colorectal cancer11Endometrial cancer11Hepatocellular carcinoma11Malignant melanoma11Nephrotic syndrome11Ovarian cancer11Glomerulonephritis membranous10Kidney transplant rejection10+272

Clinical trials in Renal and urinary disorders

580 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

580 clinical trials

Acute kidney injury

Not yet recruiting

Study on L-Glutamic Acid and Sodium Chloride to Prevent Acute Kidney Injury in High-Risk Heart Surgery Patients Without Diabetes

Registered drug
Countries:SwedenSweden
  • Participants:18–64 years · 65+ years
  • Substances:L-Glutamic Acid
  • Sponsor:Region Oestergoetland

Systemic lupus erythematosus+1

Not yet recruiting

Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azathioprine
  • Sponsor:Novartis Pharma AG

Chronic kidney disease

Not yet recruiting

Study on Finerenone for Slowing Chronic Kidney Disease Progression in Patients Receiving Standard Care

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:The George Institute For Global Health

Vesicoureteric reflux

Not yet recruiting

Study on Diagnosing Vesicoureteral Reflux in Children Using Sulfur Hexafluoride and Technetium (99mTc)

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:Sulfur Hexafluoride
  • Sponsor:Turku University Hospital

Granulomatosis with polyangiitis

Not yet recruiting

Study on Rituximab, Tocilizumab, and Tofacitinib for Patients with Granulomatosis with Polyangiitis Not Responding to Standard Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Azathioprine
  • Sponsor:Assistance Publique Hopitaux De Paris

End stage renal disease

Not yet recruiting

Study on the Safety of Glucothera Plus for Children with End-Stage Kidney Disease Undergoing Peritoneal Dialysis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Glucose Monohydrate
  • Sponsor:Iperboreal Pharma S.r.l.

Urinary incontinence

Not yet recruiting

Study on the Effectiveness and Safety of Stem Cell Therapy for Urinary Incontinence in Patients After Prostate Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Nicolaus Copernicus University

Transitional cell carcinoma

Not yet recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Bicycletx Limited

Nephrolithiasis

Not yet recruiting

Study of tamsulosin and furosemide combination therapy for patients after shock wave lithotripsy of kidney stones

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Furosemide
  • Sponsor:Region Midtjylland

Chronic kidney disease

Not yet recruiting

Study on the Effects of Finerenone, Dapagliflozin, and Ambrisentan in Patients with Chronic Kidney Disease

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ambrisentan
  • Sponsor:Steno Diabetes Center Copenhagen

Renal cell carcinoma

Not yet recruiting

Study of Axitinib and Avelumab for Patients with Localized Renal Cell Carcinoma at Moderate to High Risk of Recurrence

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Bladder cancer stage 0 with cancer in situ+1

Not yet recruiting

Study on the Safety and Effectiveness of TARA-002 for Adults with High-Grade Non-Muscle Invasive Bladder Cancer

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Streptococcus Pyogenes, Group A, Type 3, Strain Su, Inactivated
  • Sponsor:Protara Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Renal and urinary disorders trials.

Pembrolizumab52 clinical trialsNivolumab36 clinical trialsMycophenolate Mofetil24 clinical trialsDapagliflozin23 clinical trialsCabozantinib22 clinical trialsCisplatin22 clinical trialsIpilimumab21 clinical trialsGemcitabine20 clinical trialsSodium Chloride17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.